Luteolin as a multi-targeted polyphenol in pulmonary fibrosis: network pharmacology, mechanistic insights, and formulation advances

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This review reveals luteolin's therapeutic potential in pulmonary fibrosis through network pharmacology and enhanced delivery methods.

Luteolin shows promise in reducing pulmonary fibrosis via multiple molecular pathways, including TGF-β/SMAD.
In vitro studies suggest that luteolin's anti-inflammatory properties may support lung health and combat oxidative stress.
Nanoparticle-based delivery systems aim to improve luteolin's bioavailability, addressing its clinical limitations effectively.
Further investigation is essential to establish luteolin's safety and effectiveness as a treatment for chronic respiratory diseases.

Vithalkar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark